Episode 119 - Erik van den Berg - CEO of Memo Therapeutics

Prior to JPM 2026 and the news of their recent CSL collaboration, I spoke to Memo Therapeutics' CEO, Erik van den Berg for an episode of The BioHub Podcast.

Memo are preparing for a global ph3 trial of Potravitug, their antibody against BK polyomavirus infection in kidney transplant recipients. BKPyV infection can lead to nephropathy, loss of kidney function, as well as organ failure, rejection & death, with the virus residing in up to 90% of the total population.

Erik joins us to walk through Memo's late-stage plans, as well as their DROPZYLLA platform, and their early stage oncology programs. He also shares his insight from a varied journey through biotech leadership, including two current Chair roles with former BioHub guests - TargED & Step Pharma.